Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares of Stock

Posted by Lindsey Winhoffer on Feb 1st, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $11.43, for a total transaction of $22,860.00. Following the transaction, the president now directly owns 2,893,138 shares of the company’s stock, valued at approximately $33,068,567.34. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Songjiang Ma also recently made the following trade(s):

On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total transaction of $22,360.00.
On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total value of $20,980.00.
On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total value of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00.
On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.
On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total transaction of $9,560.56.
On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.40, for a total value of $24,800.00.
On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.50, for a total value of $25,000.00.

Gyre Therapeutics Price Performance

GYRE opened at $11.51 on Friday. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $26.37. The business’s fifty day simple moving average is $11.09 and its 200-day simple moving average is $12.54.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its holdings in shares of Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after purchasing an additional 43,840 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after buying an additional 90,557 shares during the period. State Street Corp raised its stake in Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after buying an additional 8,412 shares in the last quarter. Advantage Alpha Capital Partners LP purchased a new stake in Gyre Therapeutics during the third quarter worth $334,000. Finally, Renaissance Technologies LLC bought a new stake in Gyre Therapeutics during the 2nd quarter valued at $166,000. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.